Table 2.

Multivariate analysis

	Estimate (95% CI)	P
CD34-selected
CD4	0.079 (0.016 to 0.143)	.015
CD8	0.104 (0.049 to 0.159)	<.001
BM and PBSC
CD4	0.016 (−0.004 to 0.036)	.111
CD8	0.005 (−0.031 to 0.041)	.781

GEE analysis of the association of periengraftment α-diversity with the separate outcomes of CD4 and CD8 counts over the first 200 days after allo-HCT. The multivariate model was adjusted for age, total body irradiation, graft (for the unmodified grafts), ATG exposure (posttransplant), exposure to high-dose steroids, anti-CD20 antibodies, GVHD prophylaxis (calcineurin inhibitor and mycophenolate mofetil, calcineurin inhibitor, methotrexate, post-HCT cyclophosphamide–based, others, or none), cytomegalovirus risk, and incidence of GVHD. Time was included in each model as a polynomial spline.